Designing improved active peptides for therapeutic approaches against infectious diseases by Gomes, Bárbara et al.
1 
 
Designing improved active peptides for therapeutic approaches against 
infectious diseases 
 
Bárbara Gomesa,1, Marcelo T. Augustoa,1, Mário R. Felícioa,1, Axel Hollmanna,e,f, 
Octávio L. Francob,c,d, Sónia Gonçalvesa, Nuno C. Santosa,⁎ 
a Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida 
Professor Egas Moniz, 1649-028 Lisboa, Portugal 
b Centro de Análises Proteômicas e Bioquímicas, Pós-graduação em Ciências Genômicas e 
Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil 
c Programa de Pós-Graduação em Patologia Molecular, Universidade de Brasília, Brasília, DF, 
Brazil 
d S-Inova Biotech, Pós-graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo 
Grande, MS, Brazil 
e Laboratory of Molecular Microbiology, Institute of Basic and Applied Microbiology, National 
University of Quilmes, Bernal, Buenos Aires, Argentina 
f Laboratory of Biointerfaces and Biomimetic Systems, CITSE, National University of Santiago 
del Estero-CONICET, Santiago del Estero, Argentina 
 
⁎ Corresponding author. 
1 These authors contributed equally to this work. 
E-mail address: nsantos@fm.ul.pt (N.C. Santos). 
 
ABSTRACT 
Infectious diseases are one of the main causes of human morbidity and mortality. In the last 
few decades, pathogenic microorganisms' resistance to conventional drugs has been 
increasing, and it is now pinpointed as a major worldwide health concern. The need to search 
for new therapeutic options, as well as improved treatment outcomes, has therefore increased 
significantly, with biologically active peptides representing a new alternative. A substantial 
research effort is being dedicated towards their development, especially due to improved 
biocompatibility and target selectivity. However, the inherent limitations of peptide drugs are 
restricting their application. In this review, we summarize the current status of peptide drug 
development, focusing on antiviral and antimicrobial peptide activities, highlighting the design 
improvements needed, and those already being used, to overcome the drawbacks of the 
therapeutic application of biologically active peptides. 
 
1. Introduction 
In the present century, healthcare is facing diverse challenges, in 
particular the increasing number of antibiotic resistance cases (Arias 
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and Murray, 2009) and diagnosed cancers (with some of them directly 
related to chronic infections) (Arnold et al., 2015; Attiê, 2014), as well 
as the spread of novel viral strains (Bhatt et al., 2013; Skalickova et al., 
2015). The emergence of multi-resistant bacterial strains belonging to 
the ESKAPE pathogen group (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa 
and Enterobacter species) (Edwards et al., 2016), and high rates 
of viral spread, associated mostly with tropical and subtropical regions 
(Maharajan et al., 2016), have massively contributed to this public 
health problem (Dickey et al., 2017; McKenna, 2013). 
Pharmaceutical companies are facing major challenges in terms of 
drug production, costs, research and development. This has caused a 
substantial delay in launching new antibiotics on the market, not only 
due to limitations on their development, but also because of the ongoing 
evolution of those infectious agents that led to the rise in resistance 
to the drugs most widely used in the last decades. This 
phenomenon is not only related to human healthcare, but can also be 
observed in agriculture and veterinary applications (Chen et al., 2005; 
Gordon et al., 2005). As a strategy to overcome these problems, peptide 
drugs have been gaining interest, mostly due to their advantages in 
biocompatibility and target selectivity over conventional drugs, as it 
can be noticed based on a significant approval rate since the beginning 
of this century (Ahrens et al., 2012; Fotouhi, 2015). Even presenting 
high safety and ease of handling or storage, the limitations associated 
with peptide drugs are restricting their potential application (Cruz 
et al., 2004). Besides their high proteolytic degradation, limited pharmacodynamic 
and pharmacokinetic properties, the costs of production 
and the issues related to intellectual property tend to limit the development 
of such drugs (Uhlig et al., 2014). In this review, singularities 
and advances in peptide drug development will be assessed, especially 
focusing on antiviral and antimicrobial activities, in order to better 
understand the drawbacks that need to be overcome in the next few 
years. 
 
2. Peptide properties 
Peptides are among the ideal candidates to be used as an alternative 
therapeutic option, alongside conventional drugs, in different therapeutic 
fields (Lohner and Hilpert, 2016). As already mentioned, peptides 
have strong potential in terms of drug design and application, but 
even so, limitations regarding pharmacodynamics and kinetics properties 
have restricted their applicability in the pharmaceutical, agriculture 
and quality control markets (Fotouhi, 2015; Li et al., 2008; 
Lohner and Hilpert, 2016). Even with these obstacles, research regarding 
peptide activity has been extensive, with the identification of 
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different small amino acid sequences that are active towards viruses, 
bacteria, fungi or cancer cells (Falcao et al., 2014; Felício et al., 2017; 
Franquelim et al., 2010, 2008; Matos et al., 2010; Rautenbach et al., 
2016; Wang et al., 2008). Continuous research has been focused on 
simplifying the amino acid sequence, to increase stability and activity, 
as well as improving peptide pharmacological properties, facilitating 
potential application and commercialization by the pharmaceutical 
companies (Ramesh et al., 2016). 
Antimicrobial peptides (AMPs) belong to a class of peptides that was 
first described as natural peptides with activity towards different pathogens, 
and that have their origin in the innate immune system of 
different organisms (Brogden, 2005; Smith and Dyrynda, 2015). Most of 
these peptides have direct activity against bacteria, especially planktonic 
bacteria, regardless of their origin (Drusano, 2004). When bacteria 
are not planktonic, they tend to form organized complexes at the 
infection sites, where they all communicate, improving their survival 
rates (Batoni et al., 2016). These complexes, known as biofilms, may 
well have high resistance to antibiotics, but they have shown to be 
susceptible to peptides (antibiofilm peptides - ABPs) (Ribeiro et al., 
2016). Peptides can also present activity against viruses or can actively 
prevent viral infection of healthy cells (antiviral peptides - AVPs) (Hsieh 
and Hartshorn, 2016). These different types of peptides may also show 
activity towards the pathogen by recruiting immune cells (indirect activity), 
regardless of the peptide's main action. In this situation, they are 
named host-defense peptides (HDPs) (Hancock et al., 2016). Another 
class of peptides that has been gaining interest is that of cell-penetrating 
peptides (CPPs), which share some characteristics with AMPs 
(Henriques et al., 2006). CPPs have membrane translocation activity, 
with the ability to transport a small molecule cargo, which could be 
another peptide, protein, RNA or DNA (Bahnsen et al., 2015; Freire 
et al., 2017; Rodrigues et al., 2011). Peptides frequently exhibit several 
of these properties, resulting in poorly defined frontiers in terms of 
properties and mechanisms (Hale and Hancock, 2007). 
 
 
2.1. Antimicrobial peptides 
The class of AMPs has been refined in recent decades, and most 
peptides are considered less prone to promote multi-resistance in different 
pathogens (Brogden, 2005; Chen et al., 2005). Initially described 
as peptides produced by immune cells, such as neutrophils, eosinophils 
and macrophages, to fight infections (Friedrich et al., 2001; Mattar 
et al., 2016; Padhi et al., 2014; Perron et al., 2006), these peptides with 
a natural origin were later synthetically produced, as an approach to 
improve their bioactivity, by changing their amino acid sequences 
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(Schr, 2010). Considering those with natural sources, peptides can be 
isolated from animals, plants and bacteria, but the large amount of 
biological sample required and the high difficulty of expression led 
researchers to synthesize those peptides chemically, with the advantage 
of having a higher purity and yield (Meneguetti et al., 2017; Schr, 2010; 
Zasloff, 2002). This strategy allowed the emergence of synthetic AMP 
design by two different approaches. The first was to use natural AMPs 
as templates and, with small changes considering the optimal properties 
for a highly active AMP, redesign their sequence, either changing amino 
acid residues or shortening them (Cardoso et al., 2016; Migliolo et al., 
2016, 2012). The other approach was to use bioinformatics tools in the 
design of purely synthetic de novo AMPs (Hilpert et al., 2009). The 
number of AMP databases has increased, which can help researchers in 
the design process or in the screening of designed sequences (Seshadri 
Sundararajan et al., 2012; Waghu et al., 2016). More recently, mathematical 
algorithms that consider desirable antimicrobial peptide properties 
for improving activity have also been implemented, using for that 
the sequences already described in the databases (Melo et al., 2011; 
Porto et al., 2017). 
Despite their origin, antimicrobial peptides are described as small 
molecules (sequence between 5 and 50 amino acid residues), amphipathic, 
highly hydrophobic and with a positive net charge (Kang et al., 
2017). A few AMPs present negative net charge, and are also highly 
active, but these are less frequent and have been poorly described in 




Fig. 1. Distinct categories of active peptides, separated by classification and mechanism of 





structure, AMPs can be divided in α-helix, β-sheet or random coil 
(Broekman et al., 2011). Most AMPs have a random coil structure when 
in solution, adopting a well-defined conformation (usually α-helical) 
after interaction with the cell membrane of their targets (Fig. 1) 
(Brogden, 2005). An example of a peptide with an α-helical structure 
after membrane interaction is LL-37. This human-cathelicidin peptide, 
isolated from human neutrophils, is one of the most studied AMPs 
(Turner et al., 1998). Protegrin-1, isolated from porcine leukocytes, is 
an example of an AMP with β-sheet structure (Dong et al., 2014). Both 
AMPs showed high activity towards different pathogens, despite their 
different structure, which indicates that the structure alone does not 
determine their efficiency. In fact, properties such as size, charge, sequence, 
structure, hydrophobicity and amphipathicity are all important 
in defining AMP activity, and a proper balance between them is essential 
(Brogden, 2005; Hollmann et al., 2016). Additionally, this balance 
seems to be important for the lipid selectivity of the peptides, 
which may result in their antibacterial activity or cytotoxic effects 
(Alves et al., 2010; Domingues et al., 2014; Gonçalves et al., 2012a, 
2012b; Maturana et al., 2017). Even so, the relations between AMP 
properties, mode of action and target membrane composition are not 
well understood, which is noted in several studies focused only on the 
properties of similar AMP sequences (Juba et al., 2015). 
It is important to differentiate two general mechanisms of action of 
AMPs: direct membrane disruption, the most studied and the first to be 
identified, and an activity not involving membrane disruption 
(Brogden, 2005; da Cunha et al., 2016; Fjell et al., 2012). Among the 
membrane disruptive mechanisms, the toroidal pore, carpet, aggregate 
and barrel stave models were the representations developed to explain 
the different AMP modes of action at the membrane level (Hancock and 
Sahl, 2006; Melo et al., 2009; Zasloff, 2002). For instance, magainin 2 is 
an AMP that is known to promote pathogen destruction by the toroidal 
model (Campagna et al., 2007; Yang et al., 1998). Other AMPs, such as 
the extensively studied melittin or PGLa, are known to have a detergent- 
like effect on pathogen membranes (carpet model) (da Silva and 
Teschke, 2003; Naito et al., 2000). The similarity between these models 
is because the AMP leads to the membrane destabilization without any 
specific pathway or intracellular target to promote these effects, which 
could be translated in direct activity against the pathogens. In contrast, 
non-membrane disruptive mechanisms are characterized by pathogen 
targeting, leading to their destruction, without membrane disruption 
(Bechinger, 1999; da Cunha et al., 2016; Hale and Hancock, 2007). 
Even though the initial electrostatic interaction of the peptide with the 
membrane is essential to drive them towards the pathogen, these AMPs 
have specific intracellular targets, usually involved in protein, DNA 
and/or RNA synthesis and regulation, promoting the failure of specific 
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metabolic pathways or fundamental cell biology processes (Brogden, 
2005). Buforin II is one of the most studied AMPs; it has been demonstrated 
that it crosses the cell membrane and accumulates in the 
cytoplasm (Park et al., 1998). Other examples include indolicin (interferes 
with the formation of the cytoplasmic membrane), pleurocidin 
(inhibits essential nucleic acid and protein synthesis) or mersacidin 
(alters cell-wall synthesis) (Brotz et al., 1998; Friedrich et al., 2001; 
Patrzykat et al., 2002; Subbalakshmi and Sitaram, 1998). Although 
there is detailed information about different AMPs with different modes 
of action, the clear relationship between their physicochemical properties 
and activity is not well understood (Melo et al., 2011; Schr, 
2010). Nevertheless, there are some changes that have been considered 
in the design of new AMPs, such as the substitution/introduction of 
specific amino acid residues into their sequences (like arginine, lysine 
or tryptophan). Changes in the peptide net charge and a well-defined α- 
helix structure upon membrane interaction are two major characteristics 
that can improve peptide biological activity (de la Fuente-Núñez 
et al., 2015; Hilpert et al., 2005; Irazazabal et al., 2016; Mura et al., 
2016). The same specifications have also been used to design synthetic 
anti-biofilm or host defense peptides, to improve their activity. Both 
ABPs or HDPs share the same physicochemical properties as other 
AMPs, but they have different mechanisms of action towards their 
targets (Hancock et al., 2016; Pletzer and Hancock, 2016). ABPs are 
often identified as AMPs that have no activity towards planktonic 
bacteria, but are quite effective against biofilms (Ribeiro et al., 2016). 
HDPs, unlike the other examples, are described as peptides that have an 
associated immune activity, but that can also be a conventional AMP or 
ABP (Hancock et al., 2016). Natural or synthetically designed, these 
peptides can promote pathogen destruction, not through direct peptide 
action, but by recruiting immune cells to fulfil the task (Silva et al., 
2016). Other targets already described for AMPs include fungi (antifungal 
peptides) and protozoan parasites (anti-protozoan peptides) (Lee 
et al., 2017; Pimentel-Elardo et al., 2010). The number of such peptides 
described in the literature has been increasing, either from natural 
origin, or by synthetic redesign (Gonçalves et al., 2017, 2012b; Menzel 
et al., 2017). As an example, small fragments that may be efficient in 
the eradication of Candida albicans or Entamoeba histolytica were identified 
using the amino acid sequence of LL-37 (Ordonez et al., 2014; 
Rico-Mata et al., 2013). An anti-protozoan peptide, PvD1, a defensin 
isolated from Phaseolus vulgaris (common bean) seeds, has shown activity 
towards Leishmania amazonensis (do Nascimento et al., 2015). 
Nowadays, besides these strategies, the conjugation of peptides with 
different moieties, such as lipids, aromatic groups, metals or nanoparticles, 
is being tested in order to overcome some limitations in their 




2.2. Antiviral peptides 
Peptides with different therapeutic activities have been classified 
according to the target pathogen (bacteria, virus, fungi, etc.), sharing 
some features between them (Vigant et al., 2015). Cationic net charge, 
high hydrophobicity and a well-defined secondary structure upon interaction 
with membranes are among the main properties that are important 
for their activity (Skalickova et al., 2015). In this category, and 
considering AMPs as the peptides that originate from the innate immune 
system, as already described above, antiviral peptides (AVPs) 
appear naturally as peptides that are similar in physicochemical properties 
to conventional AMPs, but with a different target, namely viruses 
(Akkarawongsa et al., 2008; Augusto et al., 2017a; Gomes et al., 2017). 
As a matter of fact, there are AMPs that have dual activity against 
bacteria and viruses, either directly or by the recruitment of immune 
cells (Hsieh and Hartshorn, 2016; Skalickova et al., 2015). Considering 
the fact that patients with severe viral infections often develop later 
bacterial infection, it would be interesting to have a peptide that could 
target both pathogens. However, even with the increasing number of 
peptide drugs entering the pharmaceutical market, an effective multitarget 
peptide drug has not been developed yet (Badani et al., 2014; 
Skalickova et al., 2015). 
Antiviral peptides are characterized with the same chemical features 
as AMPs (Fig. 1), and their mechanisms of action have been extensively 
studied, with the identification of some differences in a broad 
range of viruses (human immunodeficiency virus - HIV, influenza, 
dengue or herpes viruses) (Rothan et al., 2014; Skalickova et al., 2015). 
Examples of AMPs that showed antiviral activity range from lactoferricin, 
which has activity against herpes simplex virus (HSV), latarcin, 
with activity towards dengue virus, or the different human defensins 
that were shown to inhibit HIV infection (Andersen et al., 2004; Rothan 
et al., 2014; Silva et al., 2014; Wang et al., 2008). In these examples, 
AVPs act by direct disruption of the viral envelope (in enveloped 
viruses), inhibition of viral replication (targeting the viral polymerase) 
or by inhibition of the virus-host cell membrane fusion process (Vigant 
et al., 2015; Wu et al., 2015). The first mechanism is similar to the 
direct activity of AMPs that lead to membrane disruption. LL-37 is an 
example of this, with the addition of the proven host-defense activity 
that helps the process (Currie et al., 2013; Peter Bergman et al., 2007; 
Wang et al., 2008). The inhibition of virus replication can also be induced 
by human neutrophil peptides (HNP) 1 to 4, which are also 
classified as AMPs (Hartshorn et al., 2006; Tecle et al., 2007). As a 
consequence, the virus tends to aggregate, becoming inactive in terms 




The most studied mechanism of action of antiviral peptides involves 
interference in the membrane fusion process, an essential step in infection 
by enveloped viruses. Antiviral peptides that, by strong interactions, 
block the activity of the viral fusion protein intermediates that 
are necessary for viral entry, are considered as a promising class of 
peptide drugs and have been named fusion inhibitor peptides 
(Franquelim et al., 2013; Lee et al., 2011). These peptides engage 
through electrostatic and hydrophobic interactions with the exposed 
glycoproteins of the fusion process and/or with the membrane lipids 
(Vigant et al., 2015). Enfuvirtide (T20) is an example of a fusion inhibitor 
peptide that interacts directly with the fusion proteins, binding 
also to cell membranes (Matos et al., 2010). C5A, a peptide derived 
from the protein 5A mastaporan-derived MP7, inhibits the fusion process 
by targeting membrane lipids (Cheng et al., 2008; Sample et al., 
2013; Zhang et al., 2016). The efficiency of fusion inhibitor peptides is 
directly related to the strength of the interaction and the temporal 
window of action and, initially, the capacity to diffuse and reach their 
target (Welsch et al., 2013; Zhang et al., 2016). These dependencies 
influence their possible therapeutic action. Thus, different strategies 
have been implemented to overcome the limitations described above, 
and new ones are being tested, with some examples that will be described 
later. Conjugation with different moieties, like lipid moieties or 
PEG, has also been conducted for this kind of peptide, in order to improve 
their activity, especially with those where the temporal window 
of action represents a limiting factor (Augusto et al., 2014; Hollmann 
et al., 2013; Ingallinella et al., 2009; Vilas Boas et al., 2017). 
With the aim of inhibiting the initial stage of the assembly of dengue 
virus, and also a good candidate to target also other related flaviviruses, 
the peptide inhibitor pep14-23 (Faustino et al., 2015a, 2015b) was 
designed based on a conserved intrinsically disordered domain of 
dengue virus capsid protein (Martins et al., 2012). It is intended to 
block the binding of the viral protein to intracellular lipid droplets 
(Carvalho et al., 2012; Martins et al., 2012), essential for viral replication 
(Samsa et al., 2009), as well as to nascent very low density 
lipoproteins (Faustino et al., 2014). A recently discovered peptide, urumin, 
isolated from frog skin, exhibited antiviral activity against influenza 
A virus, by targeting the conserved stalk region of H1 hemagglutinin, 
which seems crucial for the viral binding to the host cells 
(Holthausen et al., 2017). Urumin was also able to disrupt influenza 
virions; however, the underlying mechanism has not been fully determined 






2.3. Cell-penetrating peptides 
Cell-penetrating peptides (CPPs) are another class of molecules that 
share properties with AMPs, namely short amino acid sequence, positive 
net charge, high content of hydrophobic residues and well-defined 
secondary structure (Fig. 1) (Bahnsen et al., 2015; Pärn et al., 2015; 
Rodrigues et al., 2011). The difference between them lies in their activity, 
with CPPs being able to translocate to the interior of cells, 
transporting small cargos in the process (Mishra et al., 2011; Rodrigues 
et al., 2012, 2013, 2015; Skotland et al., 2015). Membrane crossing 
may occur by different mechanisms, either by direct translocation, or 
related to endocytosis, directly dependent on the peptide sequence and 
on the cargo transported (de Figueiredo et al., 2014; Mishra et al., 
2011). The cargos already tested include peptides (AMPs, AVPs or 
HDPs), large proteins, drugs, nucleic acids or nanoparticles (Freire 
et al., 2017; Gautam et al., 2013; Rodrigues et al., 2011). This major 
advantage, together with the low toxicity and low production costs, 
explains the increasing interest in CPPs (Pärn et al., 2015). The translocation 
features have still not been fully explained, but the peptide 
amphipathic character is indicated as being responsible for this. The 
hydrophobic and lipophilic moments of the CPP determine its efficiency, 
but the balance between these properties is not fully established 
(de Figueiredo et al., 2014). CPPs, although able to have a direct antimicrobial 
or antiviral activity, are clearly identified as a new method 
of intracellular delivery, with this characteristic being considered as a 
possibility for peptides that have pharmacodynamic limitations in their 
action (Henriques et al., 2006; Kristensen et al., 2016). Examples of 
peptides with dual activity are SynB1 or Pep-1-K, AMPs with potent 
direct antimicrobial activity and the ability to cross cell membranes 
carrying small molecules (Rousselle et al., 2000; Zhu et al., 2006). 
Regardless of the promising approach of using CPPs as anti-infective 
molecules, to the best of our knowledge there are currently no such 
drugs under clinical trials (Guidotti et al., 2017). 
 
3. Downsides in the therapeutic application of peptides 
Despite the intense research in peptide drugs, the number of approved 
molecules in the antibiotic and antiviral fields has not evolved 
at the same rate as resistance has emerged (Chen et al., 2005). In fact, 
the on-going search for new therapeutic molecules is mostly by chemical 
derivations of the drugs that are already on the market, a strategy 
that is not showing great advances in overcoming resistance (da Cunha 
et al., 2016). Nonetheless, it is important to list some already approved 
peptides that are being used in therapeutics (Table 1). One of the objectives 
of the research conducted at this level is to identify characteristics 
that allowed the therapeutic approval of these peptides, and 
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improve them, overcoming the drawbacks that normally limit the 
therapeutic application of these molecules (Kaspar and Reichert, 2013). 
Patients' compliance is one of the key factors in converting a product 
undergoing clinical trials into a commercialized successful drug. Peptides' 
low bioavailability, limited by their degradation and low epithelial 
absorption, is the leading difficulty in the therapeutic application 
of peptides (Hamman et al., 2005). The oral delivery of peptides 
leads to their degradation by gastric acids, as well as by proteases and 
peptidases present in the gastro-intestinal (GI) tract. Even if the peptide 
escapes this degradation route, approximately 80% face another challenge 
soon afterwards: the intestine's epithelial barrier (Bruno et al., 
2013). At the epithelial barrier, peptides have to overcome the mucosal 
layer, composed of glycoproteins, glycocalyx, mucopolysaccharides, 
enzymes, electrolytes and water; the brush border membrane with 
microvilli; and the efflux pumps, which can pump the peptide back into 
the GI lumen after its absorption (Carino and Mathiowitz, 1999). 
In addition, after absorption, peptides face some difficulties, such as 
the first-pass effect. When absorbed, they enter the hepatic portal 
system and are likely to be metabolized by the liver, reducing the 
concentration that actually enters systemic circulation (Bruno et al., 
2013). To overcome this limitation, the delivery of the peptides may be 
carried out through different routes, such as intravenously, subcutaneously 
or intramuscular. However, classical routes of administration 
do not guarantee efficient peptide delivery to its site of action. In 
fact, endogenous proteases may also lead to proteolytic degradation, 
and chemical modifications can also occur. Sieprawska-Lupa et al. 
studied the susceptibility of LL-37 to proteolytic degradation by two 
major proteinases, both produced by Staphylococcus aureus, a metalloproteinase 
(aureolysin) and a glutamylendopeptidase (V8 protease) 
(Sieprawska-Lupa et al., 2004). They found that aureolysin cleaved and 
inactivated LL-37 in a time- and concentration-dependent manner, directly 
affecting the peptide's bactericidal effect (Sieprawska-Lupa et al., 
2004). Temperature, pH or high salt concentrations can alter the native 
structure of the peptide and/or their interaction with membranes, resulting 
in inactive molecules in circulation. The influence of salt concentration 
on AMP activity was studied by Turner et al., who reported 
the effects of NaCl in the minimal inhibitory concentration (MIC) of LL- 
37 (Turner et al., 1998). In a medium with 100 mM NaCl, some organisms 
became resistant to the peptide, in comparison to a low-salt 







List of peptides FDA-approved to be used in therapeutics, based in their sequence, company, 




Unlike other protein-based drugs, peptides exhibit lower potency 
due to their short half-life. Antibodies, for instance, which are well 
established in the pharmaceutical industry, may present elimination 
half-lives of several days, maintaining a constant concentration in the 
bloodstream (Tang et al., 2004). Besides, most of the peptides used in 
clinical practice are for extracellular compartments and, thus, have to 
compete with biologic products (Fotouhi, 2015). These pitfalls can lead 
to fast peptide clearance or its accumulation in non-target organs or 
tissues, implying a higher dosage administration, which may be associated 
with toxicity and higher production costs (Sachdeva, 2016). In 
parallel with the pharmacokinetic disadvantages, regulatory agencies 
are struggling to come up with a global set of guidelines defining the 
minimum purity for peptide therapeutics, mainly due to two reasons: 
first, peptide impurities are not easy to avoid; secondly, to produce a 
higher quality product, with less impurities, the manufacturing costs 
would increase so that the drug becomes economically unfeasible 
(Sachdeva, 2016). 
 
4. Different methods for improved peptide design 
The design of new peptides or analogues can be a daunting task, 
considering the number of parameters that must be fulfilled in order to 
have an ideal candidate. There are three key elements that should be 
carefully thought through in the design and optimization of peptides: 
the pathogen, the host and the manufacturing costs. Regardless of the 
action/target of the peptide, host cell toxicity, biodistribution and 
protease resistance are important factors to take into account in the 
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drug development process, as described above (Cytryńska and 
Zdybicka-Barabas, 2015; Kim et al., 2014). Cell, membrane or protein 
selectivity is also a major point that should be addressed during peptide 
optimization (Costin et al., 2010; Matsuzaki, 2009). From the therapeutic 
point of view, the administration of peptides should cause no or 
minimal side effects. At the industrial level, the production costs must 
be as low as possible. In order to meet this criterion, peptides with short 
sequences are preferentially selected (Craik et al., 2013). The design of 
peptides with few amino acid residues is challenging and should not 
compromise their activity. Although there is a high supply of peptide 
when the production cost is low, some have reported that high 
production levels can cause a decrease in peptide activity/stability due 
to aggregation in oral formulations (Bak et al., 2015). To overcome 
such problems, new methodologies should be applied to modify the 
properties of the peptides. 
Many approaches have been developed over the years to generate 
new peptide sequences, for different targets, based on known peptide 
databases. Computational design is a very powerful tool that has been 
refined over time, in which a given peptide/protein sequence can be 
submitted to one of the available web tools in order to be profoundly 
analysed regarding its physicochemical properties. Important information 
is given by these tools, through which new active peptides may be 
predicted based on the input sequence (Dias et al., 2017; Wang et al., 
2011). In many cases, the aim is to optimize a known peptide sequence 
to be more resistant to proteases or efficient towards the target cell or 
protein. One of the strategies is the substitution of L- for D-amino acids, 
to increase protease resistance (Di Grazia et al., 2015). Hydrophobicity 
is also a parameter that influences the behaviour of peptides with antimicrobial 
or antiviral activity. The lipid membrane is involved in the 
function of these two types of peptides in different ways. AMPs first 
target the membrane, to destroy it, while several AVPs use it as an 
intermediate to be close to viral proteins upon viral entry. Besides the 
common amino acid modification to introduce hydrophobicity, the 
conjugation of sterols or fatty acids is increasing the repertoire of new 
modifications that positively influence the activity of the peptides 
(Krishnakumari and Nagaraj, 2015; Pessi, 2015). Covalent attachment 
of polyethylene glycol (PEG) chains, known as PEGylation, offers increased 
half-life and improved solubility, without causing an immunogenic 
reaction in the host (Hamley, 2014). Altogether, these two 
modifications combined have been successfully used to improve the 
activity of peptides (Augusto et al., 2014; Pessi et al., 2012; Porotto 
et al., 2010; Welsch et al., 2013), but also of antibodies (Augusto et al., 
2017b; Lacek et al., 2014). Some peptides just need to be proteaseresistant 
to reach their target, while others might need a vehicle to 
travel to their destination (Pessi, 2015), still others are intrinsically able 
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to permeate membranes, which is the case of CPPs (Kauffman et al., 
2015). The latter have been widely used to improve cell delivery, as 
described above, by their conjugation with nanoparticles, liposomes or 
biomolecules, such as small interference RNA (siRNA) and essential 
proteins, both in vitro and in vivo (Freire et al., 2017; Jo et al., 2014; 
Kwon et al., 2015). Peptides are involved in a vast number of applications, 
and their development using computational techniques and 
chemical modification approaches will be addressed below. 
 
Table 2 




4.1. In silico approaches to predict and design new peptides 
The prediction of new peptide sequences or properties of the already 
described active peptides by algorithm databases has been gaining interest 
in the era of “big data” (Table 2). CPPs have been extensively 
studied as a delivery option for bioactive molecules that are poorly 
taken up by cells (Raucher and Ryu, 2015). To the best of our knowledge, 
CPPsite 2.0 is the only online database fully dedicated to experimentally 
validated CPPs (Agrawal et al., 2016). This website includes 
access to articles and patents with very detailed information 
regarding peptide sequence, length and chemical modifications, as well 
as the cell lines used for CPP evaluation. Many other important parameters 
are present in the website, which comprises 1699 unique and 
experimentally validated CPP sequences (Agrawal et al., 2016). CPPsite 
2.0 allows the users to create their own dataset to be used by online 
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tools dedicated to the prediction of efficient CPPs. CPPpred (Holton 
et al., 2013) and CellPDD (Gautam et al., 2013) are the two major and 
free web servers that have used CPPsite 2.0 as their dataset. CPPpred is 
a neural network-based in silico method, which can predict CPPs ranging 
from 5 to 30 amino acid residues (Holton et al., 2013). This web 
server can only evaluate the input sequence, by calculating the probability 
of the peptide to be cell penetrating. CPPpred scores the input 
sequence between 0 and 1, in which a score above 0.5 indicates that the 
peptide has a high chance of being cell penetrating, while a score close 
to 0 suggests that the peptide is very unlikely to be cell penetrating. The 
closer the score is to 1, the higher is the CPPpred degree of confidence 
to classify the peptide as cell penetrating. CPPpred is an efficient tool to 
predict if a given peptide sequence has the ability to be CPP or not, but 
it cannot help in the design of new peptides (Holton et al., 2013). In 
contrast, CellPDD is a web server that offers more tools, in which new 
peptide sequences can be predicted based on the input sequence 
(Gautam et al., 2013). The server generates all possible substitution 
mutants of the query peptide, and classifies them according to the cell 
penetrating prediction, also giving information about physicochemical 
properties such as charge, hydrophobicity and other parameters relevant 
for their activity (Gautam et al., 2013). In the case of larger 
proteins, their sequences are analysed in terms of possible CPP motifs. 
Due to the extensive studies of AMPs, there was a need to create 
AMP databases, covering peptides from prokaryotes, eukaryotes 
(Seshadri Sundararajan et al., 2012; Waghu et al., 2016; Wang et al., 
2016), bacteria (Hammami et al., 2010), defensins (Seebah et al., 2007) 
and peptaibols (soil fungi antiviral and antimicrobial peptides) 
(Table 2) (Whitmore, 2004). The authors of CellPDD and CPPsite 2.0 
created AntiBP2, a web server that contains the necessary tools to 
predict new AMPs based on peptide sequences (Lata et al., 2010). 
During literature analysis, authors found that certain amino acids are 
preferred at the C- or N-terminal of AMPs, a key finding for the discrimination 
of non-antimicrobial peptides. In response to this outcome, 
Lata et al. (2010) created a more robust model to predict new sequences. 
In addition, AntiBP2 can also give information about the potential 
source and family of the input sequence (Lata et al., 2010). 
Antibiofilm peptides are a niche inside the AMP category that can 
target and destroy highly structured and organized populations of 
bacteria (biofilms). The first manually curated database for this class of 
peptides was only recently created (Di Luca et al., 2015). Biofilms are 
being recognized as the principal cause of a wide range of infections 
and are easily recognized in post-surgical infections on implants 
(Connaughton et al., 2014) or in chronic infections like cystic fibrosis 
(Høiby et al., 2010). The need for new antibiotic molecules led to the 
creation of a web server fully dedicated to the prediction and design of 
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antibiofilm peptides – Design Peptides Against Bacterial Biofilms 
(dPABPs) (Sharma et al., 2016). 80 ABPs from biofilm-active AMPs 
database (BaAMP) were used as the positive dataset in the optimization 
of the implemented model in this web server. The positive dataset includes 
only peptides that were able to disrupt biofilms from all species 
tested against, which exclude those shown to be active against only one 
or two different strains. The aim of dPABBs is to find broad-spectrum 
peptides active against multiple bacterial species (Table 2). 
AVPs are another important group of peptides with therapeutic use 
(Table 2). There is a need to speed up the discovery of effective new 
AVPs to treat deadly human viruses, mostly because some viruses create 
a pandemic cycle worldwide, with the help of globalization. The Antiviral 
Peptide database (AVPdb) is a manually curated database dedicated 
to antiviral peptides, targeting 60 clinically important viruses 
(Qureshi et al., 2014). This database comprises 2683 antiviral peptides 
experimentally validated, in which 624 are modified peptides. Information 
regarding sequence, source, targeted virus, and tested cell 
lines can be found in the database. Besides AVPdb, there is an anti-HIV 
peptide database that provides experimental records of 981 peptides 
targeting different steps during the life cycle of HIV (Qureshi et al., 
2013). The same authors developed a web server that allows the prediction 
of potent antivirals, and the design of new peptide analogues 
(Qureshi et al., 2017). Four individual prediction models for HIV, hepatitis 
C virus, hepatitis B virus and human herpes virus were created, 
and a fifth generalist model was implemented for another 26 human 
viruses. The value of this web server is that it makes it possible to 
predict potential new antiviral therapeutics with great efficiency. 
Clearly, detailed databases have been built to help researchers in the 
design of active peptides. More importantly, a wide range of tools was 
developed to predict how likely it is that an input sequence belongs to a 
known class of biologically active peptides, or not, and which modifications 
can be made to turn inactive sequences into active ones. 
However, it is important to mention that in vitro optimization does not 
guarantee increased in vivo activity. 
4.2. Strategies to improve peptide half-life 
Peptides are in general better drug candidates than other chemical 
compounds, considering properties related to toxicity and activity 
(Fig. 2). Peptides can be easily eliminated from the body, generally 
resulting in a safer choice for therapeutic use. During peptide optimization, 
one of the most important improvements is protease resistance, 
leading to an increase in the peptide's half-life (Cromm et al., 2016; 
Heard et al., 2013; Stromstedt et al., 2009; Tugyi et al., 2005; 
Weinstock et al., 2012). A large number of papers regarding peptide 
modifications that aim to extend their bioavailability and improve both 
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biodistribution and rate of clearance have appeared in the literature. 
Strategies include N- and C-modifications, incorporation of non-natural 
or D-amino acids, cyclization and PEGylation (Gentilucci et al., 2010; 
Vlieghe et al., 2010; Weinstock et al., 2012). Recently, a manually 
curated library of experimentally validated peptide half-lives, named 
PEPlife, was created (Mathur et al., 2016). Sequences and modifications 
were organized, together with the peptide biological activities, for a 
total of 2229 peptide entries, divided into linear (1984) and cyclic 
(245) peptides. 
Proteases responsible for peptide degradation are mainly present in 
the digestive tract and blood plasma, resulting in low peptide bioavailability 
(Vlieghe et al., 2010). The liver and kidneys are also involved 
in the fast clearance of peptide metabolites. The proteolytic 
degradation of peptides can be addressed by protecting their C- and Nterminus, 
with acetylation or amidation (John et al., 2008; Stromstedt 
et al., 2009). A relevant strategy for overcoming peptide hydrolysis is to 
perform modifications on the sequence by substitution of natural Lamino 
acids for their D-enantiomers, α/β-substituted α-amino acids or 
even β-amino acids (Gentilucci et al., 2010; Vlieghe et al., 2010). DAmino 
acid substitution in a peptide may have implications not only for 
the peptide's stability, but also for its activity and secondary structure 
 (Cappiello et al., 2016). A full replacement of the L- by D-amino acid 
residues within the peptide results in an enantiomer, while partial 
substitutions in the sequence can produce different diastereomers. 
Hong et al. (1999) compared several D-diastereomers and a D-enantiomer 
of an AMP in terms of stability, structure and activity. Interestingly, 
the substitution for D-amino acids in the middle of the peptide 
sequence was able to disrupt the α-helical structure of the peptide and 
abolish its antimicrobial activity, in contrast to the D-enantiomer, where 
the structural and activity parameters were maintained (Hong et al., 
1999). Changes at both C- and N-termini of the peptide did not affect its 
α-helical conformation or antimicrobial activity, but improved the 
peptide's stability in the presence of serum (Hong et al., 1999). Membrane 
binding can also be affected by partial D-amino acid replacement, 
as it was shown for an AMP extracted from frog skin, whose membrane 
binding was increased and β-sheet aggregates reduced (Mangoni et al., 
2006). Di Grazia et al. (2015) reported that a natural-derived peptide, 
named esculentin-1a(1-21)NH2, with two D-amino acids in its sequence, 
was able to be more stable in serum, less toxic to mammalian cells and 
more effective against bacterial biofilms, while keeping its high activity 
against planktonic P. aeruginosa. In a different study, de la Fuente- 
Núñez et al. (2015) showed that the peptides DJK-5 and DJK-6, both 
composed only of D-enantiomers, destroyed 7 species of preformed 
biofilms and 30 strains of wild-type and multi-drug-resistant pathogens. 
The use of non-natural amino acid residues, like fluorinated leucine, in 
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the sequence of antimicrobial peptides was also reported to increase 
bactericidal activity and protease resistance (Meng and Kumar, 2007). 
The use of D-amino acids in peptides based on human β-defensins improved 
their biological activity (Olli et al., 2013). In the antiviral field, 
cationic peptides with β-amino acids were able to inhibit HSV type 1 
infection (Akkarawongsa et al., 2008). 
Cyclotides are naturally backbone-cyclized peptides expressed by 
plants that have enhanced thermal, chemical and enzymatic stability 
(Gould and Ji, 2011). Efforts have been made to develop cyclic peptides, 
by bridging cysteine residues (disulfide bond) or by connecting Nand 
C-terminus via an amide bond. Cyclization of bioactive peptides is 
often associated with improved stability and activity of the molecule 
(Joo, 2012). In the antiviral battle against dengue virus, a peptide extracted 
from cone snail venom was found to be a good inhibitor of a 
protease involved in the virus' replication cycle (Xu et al., 2012). A 
mutational study showed that the cyclized version of this peptide led to 
a stable conformation, able to bind and inhibit the viral protease more 
efficiently (Xu et al., 2012). An AMP named gomesin, isolated from the 
Brazilian spider Acanthoscurria gomesiana, was found to be not only 
bactericidal and fungicidal, but also cytotoxic against tumour cells 
(Chan et al., 2013). The authors of this study proved that the cyclization 
of gomesin improves the stability of the molecule, also enhancing its 
antitumor activity, without changing its toxic effects on healthy cells. 
Arginine residues are one of the major constituents of cell penetrating 
peptides, and have been used to create polyarginine-based CPPs 
(Tung and Weissleder, 2003). In particular, a linear peptide made of 
only nine arginine residues (R9) was found to be as potent as TAT (a 
classic HIV-derived CPP) in crossing membranes (Futaki et al., 2001). 
The positively-charged guanidinium group of arginine is involved in the 
interaction with the phospholipids of the membranes (Bouchet et al., 
2010), a crucial feature for efficient cell penetration. Stiffening the 
peptide backbone by synthesizing macrocycles was a strategy followed 
by Traboulsi et al. (2015), in which R9-based peptides were used as a 
model to generate new proteolytic stable cyclic CPPs. A hepta-arginine 
macrocycle was found to be as efficient as the linear R9. 
As previously mentioned, another possible strategy is the 
PEGylation of peptides and proteins, a well-known chemical approach 
for overcoming the low bioavailability of molecules in the human body. 
The attachment of the polyethylene glycol polymer to peptides enables 
a longer circulation time, in which water solubility and molecule stability 
are both improved (Hamley, 2014; Mathieu et al., 2017; Thieme 
et al., 2016; Yin et al., 2016). A synthetic AMP named M33, active 
against Gram-negative bacteria, was conjugated with PEG at the Cterminus, 
resulting in a great stability against elastase, a protease from 
P. aeruginosa (Falciani et al., 2014). Some authors reported that antiviral 
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peptides designed to inhibit HIV-1 infection presented decreased 
antiviral activity upon conjugation with PEG (Falciani et al., 2014). 
However, this inconvenience was compensated for by increasing peptides' 
proteolytic resistance and longer half-life time in circulation 
(Danial et al., 2012). 
4.3. Targeting lipid membranes 
The membrane, either from the pathogen or the host, is the major 
intervenient in the mechanism of action of several peptides. In the case 
of AMPs, the most common aim is to compromise bacterial viability, 
either by acting directly at the membrane level or by acting on specific 
intracellular targets. Antiviral peptides may use the membrane of 
healthy cells as a reservoir to target the viral protein of interest and 
prevent the infection process (Vigant et al., 2015). Membrane interactions 
may also induce conformational changes or define the orientational 
disposition of peptides, facilitating the interaction with the viral 
target (Avitabile et al., 2016; Faustino et al., 2015a; Melo et al., 2009). 
There is also the case of CPPs that can target both healthy and nonhealthy 
cells to deliver any type of therapeutic molecule. In the end, 
chemical composition, as well as peptide structure, will influence biological 
activity. In the literature, hydrophobicity is a parameter that is 
often described as undesirable and that leads to peptide aggregation or 
formulation issues. However, it is essential to find a balance in the 
peptide composition in order to allow a good in vivo activity and optimal 
conditions to be used in therapeutic settings. Some authors 
achieved an increase in peptide hydrophobicity by substituting alanine 
residues with leucines, known to be more hydrophobic (Chen et al., 
2007). Bulky amino acids such as tryptophan and phenylalanine were 
used as sequence end-tags, to guide peptides to membranes (Pasupuleti 
et al., 2009), due to their ability to locate among the polar headgroups 
of phospholipids, close to the lipid-water interface (Chan et al., 2006). 
There is the case where an increased membrane interaction was obtained 
by simple substitution of amino acid residues, but cytotoxic and 
haemolytic effects accompanied the increase in peptide hydrophobicity 
(Hollmann et al., 2016). To avoid these side effects, new strategies have 
been applied to increase peptide membrane targeting, without changing 
the amino acid sequence. The chemical conjugation of sterols or 
fatty acids to peptides is a recent trend used in the antiviral and antimicrobial 
fields (Chu-Kung et al., 2010; Pessi, 2015). This approach led 
to a rise in interest in lipopeptides, either from natural (Eisenstein et al., 
2010; Moryl et al., 2015) or non-natural origins (Pessi, 2015). 
The derivatization of peptides with fatty acids increases not only 
membrane affinity, but also their half-life in circulation (Pollaro and 
Heinis, 2010; Zhang and Bulaj, 2012). Conjugation can be done at the 
N-terminal, or in the amino acid side-chains of lysine or cysteine residues. 
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The fatty acids that are commonly used for this purpose have a 
variable number of backbone carbons, including caprylic acid (C8), 
capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid 
(C16), stearic acid (C18) and eicosanoic acid (C20). An antimicrobial 
peptide named A2 was conjugated at the N-terminus with fatty acids of 
different chain lengths (C8–20), and was afterwards tested in terms of 
biological activity (Húmpola et al., 2017). Authors found that fatty 
acids up to C14 were the best at increasing the antimicrobial activity of 
A2, while longer chains promoted toxicity to eukaryotic cells. Lee and 
Tung (2010) reported that CPPs conjugated to C16 were harmful to 
cells, in comparison to shorter fatty acid chains (C12–14). A balance 
between the length of the fatty acid chain and the sequence of the 
peptide is necessary to optimize the toxicity and activity of the peptide. 
The short chain of myristic acid, associated with low toxicity, makes it 
one of the most appropriate fatty acids for use in conjugation to peptide 
analogues of human defensins. Other authors (Mathew and Nagaraj, 
2015a, 2015b) designed and synthesized analogues of human α-defensins 
5 and 6 conjugated to myristic acid. They found that N-terminal 
fatty acylation improved the antimicrobial activity of the analogues, 
where permeabilization of the membranes was suggested as the mechanism 
of action. Sharma et al. (2015) took the interesting approach of 
generating truncated linear versions of the cyclic human β-defensin 4. 
The new peptides were myristoylated, and were as potent as the original 
human defensin, exerting its activity by crossing the cell membrane. 
A recent study revealed the use of myristic acid in CPPs aiming 
to deliver siRNA across the blood-brain barrier to treat neurodegenerative 
diseases (Youn et al., 2014). 
Apart from fatty acylation, sterol conjugation is a related strategy to 
increase membrane targeting. While the library of fatty acids reported 
in the literature comprises different options, the used sterols have been 
mostly restricted to cholesterol and α-tocopherol (Arnusch et al., 2012; 
Figueira et al., 2017; Hollmann et al., 2013; Mathieu et al., 2017; Pessi, 
2015). Lipid membranes may include different sterols in their composition, 
and these play important roles such as the maintenance of 
membrane microfluidity (Dufourc, 2008). In vertebrates, the major 
sterol is cholesterol (Hannich et al., 2011), while fungi present mainly 
ergosterol (Hannich et al., 2011). Primitive bacteria present hopanoids, 
which are developed in extreme environmental conditions (Hannich 
et al., 2011). Sterols are important not only in the membrane fluidity, 
but also in the formation of ordered nanodomains, often named lipid 
rafts, which are considered to be involved in several biological processes, 
including viral infections (Barman and Nayak, 2007; Carter 
et al., 2009). 
Cholesterol was conjugated to the HIV-1 derived peptide C34, with 
the purpose of increasing peptide-membrane affinity (Ingallinella et al., 
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2009). In theory, the concentration of the cholesterol-conjugated peptide 
would increase at the site where HIV entry takes place. Later, 
Hollmann et al. proved this hypothesis, suggesting the membrane as a 
catalyst for the binding between the antiviral peptide and the HIV-1 
protein gp41, by placing and concentrating the peptide in specific domains 
at the membrane (lipid rafts), in a manner that favours its activity 
(Hollmann et al., 2013). In agreement with this hypothesis, Zhang 
et al. reported an increase both in the antiviral activity and in the 
membrane retention of CP32M (anti-HIV fusion peptide) when conjugated 
with cholesterol (Zhang et al., 2016). The combination of PEGylation 
and cholesterol in one molecule is a dual strategy aimed at 
improving membrane targeting to boost antiviral activity. Fusion inhibitor 
peptides against measles virus and HIV-1 were conjugated with 
PEG and cholesterol, with a dramatic increase in their antiviral activity 
and half-life (Figueira et al., 2017; Mathieu et al., 2017; Pessi et al., 
2012). The presence of spacers of PEG between the N-terminal of the 
peptide and the cholesterol molecule allows increased mobility, which 
apparently favours interaction with the viral protein, reducing spatial 
restrictions (Augusto et al., 2014). The same trend was also observed 
for HIV broadly neutralizing antibodies upon PEG and cholesterol 
conjugation (Lacek et al., 2014), where strong binding to lipid membranes 
was observed (Augusto et al., 2014; Augusto et al., 2017b). 
Cholesterol conjugation strategies have also been used in a wide variety 
of studies to improve the biologic activity of peptides against more 
deadly viral pathogens, such as Nipah virus (Porotto et al., 2010) and 
Ebola virus (Higgins et al., 2013). It was also reported in the literature 
that cholesterol-conjugated peptides can efficiently block endosomefusing 
enveloped viruses, such as influenza virus (Lee et al., 2011). 
The development of lipopeptide vaccines that promote the immune 
response of the organism using peptides mimicking viral epitopes is 
being considered a valid option in vaccine design (Zaman and Toth, 
2013). Palmitoylated peptides based on HIV-1 proteins (Nef, Gag and 
Env) were tested in clinical trials, and a boost in cytotoxic lymphocyte 
(CTL) levels was observed, which indicates an enhanced response of the 
immune system when challenged with lipopeptides (Gahéry-Ségard 
et al., 2003). Additionally, a lipopeptide vaccine based on a human 
cytomegalovirus CTL epitope was able to induce an antigen-specific 
CTL response, which killed infected human cells (Diamond et al., 1997). 
HSV type 2 was also targeted in the development of lipopeptide vaccines, 
with strong CTL response (Zhang et al., 2009). Recently, Morita 
et al. described the important role of a new class of MHC class I molecules, 
which are able to present N-myristoylated lipopeptides to CTL 
(Morita et al., 2016). N-myristoylation of proteins or peptides is linked 
to pathogenesis and CTL ability to sense this post-translational modification, 
which could indicate the pertinence in vaccine design, since it 
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is unlikely for a virus to mutate the N-terminal without affecting the 
protein function (Boso et al., 2015; Brenner et al., 2006; Gastaminza 
et al., 2003). Thus, it would be hard for viruses to evade lipopeptidespecific 
CTL response (Morita and Sugita, 2016). 
 
 
Fig. 2. Different approaches for the improvement of the half-life of peptides. 
 
5. Future prospects 
The therapeutic peptide market is an emerging field that is currently 
growing. The failure of several small molecules, which led to substantial 
economic losses in the pharmaceutical industry, and the decrease 
in innovation concerning classical active ingredients led to investment 
in peptide-based drugs, and consequently, the appearance of 
several therapeutic peptides with distinct targets (Lax, 2010). The 
methods referred to above offer opportunities for improving the functionality 
of peptides, and for increasing the number of targets considered 
suitable for drug development. The approval of enfuvirtide, a 
fusion inhibitor peptide for HIV, is considered the turning point in drug 
nature policies, since it changed the investors' attitude to biotech in 
general and to peptides in particular (Otvos, 2008). The FDA approval 
rate confirms this progression. While the number of new chemical entities 
has been stable for about 10 years, the number of approved 
peptides has been continuously growing, and those already on the 
market presented an increased volume of sales during this period 
(Vlieghe et al., 2010). According to Craik et al., the market for proteinand 
peptide-based drugs represents about 10% of the total pharmaceutical 
market, and it is increasing (Craik et al., 2013). Numerous 
scientific publications demonstrate the intense basic research in this 
field, with thousands of peptides being studied, and 400 to 600 of them 
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are enrolled in preclinical studies (Sachdeva, 2016). Moreover, a large 
number of peptides are currently in clinical trials, with a high probability 
that some of these will be approved as pharmaceutical drugs in 
the near future (Ahrens et al., 2012). Recently, several strategies regarding 
large-scale production of peptides have been improved, and 
these are expected to speed up the drug discovery phase. As a result, the 
entrance of a candidate into clinical phases is faster, in comparison with 
small organic molecules. Furthermore, peptides do not present as many 
side effects as classical drugs, which increases the rate of regulatory 
approval by about 20% (Fox, 2012). In 2012, the FDA launched the 
antibacterial drug development task force, in order to increase the efficiency 
of antibiotic development, including clinical trial design (Fox, 
2012). Overall, the reduction of time for the development of a new 
therapeutic product will directly influence the economic value of the 
final product, making the peptide entity very desirable for the pharmaceutical 
industry (Lax, 2010). A better understanding of the basic 
biology involved in different pathogens' infections will allow the 
identification of drug targets based on protein-protein interactions, 
which could increase the importance of peptides in the pharmaceutical 
field even more (Faustino et al., 2014, 2015a; Kovalainen et al., 2015). 
Nevertheless, as noted before, peptides also present some limitations 
that need to be addressed, which are technical hurdles for the 
development of more effective peptide-based therapeutics. First, the 
synthesis of peptides must be rethought. Apart from a few exceptions, 
current strategies rely on expensive coupling reagents, resins and protected 
amino acids, creating the need for cheaper synthesis and purification 
methods (Pattabiraman and Bode, 2011). The improvement of 
pharmacokinetic properties is another challenge for the next generation 
of peptide-based drugs. A special effort should be made to improve the 
interaction of peptides with membranes, increasing protease resistance 
and reducing their clearance (Craik et al., 2013). Another concern to 
have in mind is the delivery of peptides to their specific target. For a 
number of years, drug delivery systems appeared just after the drug 
approval, frequently as a method of outliving the end of the patent and 
extending it, but the paradigm has changed; nowadays, these delivery 
systems are being developed as part of a therapeutic formulation 
(Albericio and Kruger, 2012). 
The natural sources from which active peptides can be isolated are 
virtually unlimited. Thus, the appearance of potent new peptides will 
not stop, as can be exemplified by the recent case of the first isolated 
fungal defensin, which showed promising anti-infective therapeutic 
action (Mygind et al., 2005). In parallel with their growth as therapeutic 
options, it is expected that in the future peptides will also be 
used as functional foods and nutraceutics, as vaccines, in diagnostics, in 
the cosmetic field or even in agriculture to control pests (Kovalainen 
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et al., 2015). With the advances that are arising in this field, the potential 
of peptide drugs is enormous, and during the next few decades, 
peptides will probably assume a leading role in modern medicine and 
pharmaceutics. 
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